中国组织工程研究

中国组织工程研究 ›› 2010, Vol. 14 ›› Issue (45): 8478-8482.doi: 10.3969/j.issn.1673-8225.2010.45.028

• 干细胞学术探讨 stem cell academic discussion • 上一篇    下一篇

间充质干细胞治疗自身免疫性疾病及其细胞生物治疗的致瘤性

黄金棋，林艳娟   

  1. 福建医科大学附属协和医院血液科，福建省血液病研究所，福建省福州市  351100
  • 出版日期:2010-11-05 发布日期:2010-11-05
  • 通讯作者: 林艳娟，博士，主任医师，福建省血液病研究所，福建省福州市 351100 yjlin88@yahoo.com
  • 作者简介:黄金棋★，男，福建省莆田市人，汉族，2010年福建医科大学毕业，硕士，医师，主要从事干细胞移植方面的研究。 florahjq@163.com
  • 基金资助:

    福建省自然科学基金课题(C0710014)。　

Mesenchymal stem cells for treating autoimmune diseases and its oncogenicity of cell biotherapy

Huang Jin-qi, Lin Yan-juan   

  1. Department of Hematology, Union Hospital Affiliated to Fujian Medical University, Fujian Institute of Hematopathy, Fuzhou  351100, Fujian Province, China
  • Online:2010-11-05 Published:2010-11-05
  • Contact: Lin Yan-juan, Doctor, Chief physician, Department of Hematology, Union Hospital Affiliated to Fujian Medical University, Fujian Institute of Hematopathy, Fuzhou 351100, Fujian Province, China yjlin88@yahoo.com
  • About author:Huang Jin-qi★, Master, Physician, Department of Hematology, Union Hospital Affiliated to Fujian Medical University, Fujian Institute of Hematopathy, Fuzhou 351100, Fujian Province, China florahjq@163.com
  • Supported by:

    the Natural Science Foundation of Fujian Province, No. C0710014*

PDF

351

被引次数

3

摘要：

背景：间充质干细胞可分泌多种细胞因子，亦可通过与免疫细胞的直接接触参于对免疫细胞(抗原提呈细胞、T细胞、B细胞、自然杀伤细胞等)细胞间通讯信号的调节，诱导对自身抗原的特异性免疫耐受或特异性免疫无应答。此治疗性策略对自身免疫病具有重要意义，部分学者也开始在自身免疫病动物模型上尝试、验证这一策略。
目的：了解间充质干细胞在自身免疫病领域的应用进展。
方法：由第一作者检索2005/2010 PubMed数据库(http://www.ncbi.nlm.nih.gov/PubMed)及OVID数据库(http://gateway. ovid.com)有关间充质干细胞的免疫特性、作为细胞治疗手段用于自身免疫病治疗，以及间充质干细胞致瘤性等方面的文章，英文检索词为“Mesenchymal stem cell, immune characteristics,cell-based therapy, autoimmune disease, oncogenicity”，排除重复性研究。共保留其中的31篇归纳总结。
结果与结论：间充质干细胞本身具有的免疫特性及干细胞所具有的定向分化性质，使其明显区别于传统免疫抑制药物，作为一种新型生物治疗方法，间充质干细胞开启了继造血干细胞之后自身免疫性疾病应用细胞生物治疗的可能。相关致瘤性问题如何进一步明确并加以有效预防，这有利于其在临床的推广应用，今后可能成为间充质干细胞相关领域研究的主要方向。间充质干细胞在自身免疫病的临床应用尺度、适应证应严格把握，取代作为临床一线药物治疗自身免疫病的传统免疫抑制剂的地位证据不足。

关键词: 自身免疫病, 间充质干细胞, 免疫特性, 细胞治疗, 致瘤性

Abstract:

BACKGROUND: Mesenchymal stem cells (MSCs) can participate in regulating communication signal between immune cells (antigen presenting cell, T cell, B cell, natural killer cell and so on) and induce autoantigen-specific immune tolerance or immunological unresponsiveness by secreting a variety of cytokines and cell-cell contact. This therapeutic strategy makes great significance to auto-immune disease. Some scholars began to try and validate this strategy on autoimmune disease animal models as well.
OBJECTIVE: To understand application progress of MSCs in the field of auto-immune disease.
METHODS: The first author searched PubMed database (http://www.ncbi.nlm.nih.gov/PubMed) and OVID database (http://gateway.ovid.com) for literatures concerning MSC immune characteristics, MSCs as a cell therapy manner for auto-immune disease and MSC oncogenicity published from 2005 to 2010. Key words were “Mesenchymal stem cell, immune characteristics, cell-based therapy, autoimmune disease, oncogenicity”. Duplicate articles were excluded. Finally, 31 articles were selected.
RESULTS AND CONCLUSION: Auto-immune characteristics of MSCs and directional differentiation characteristics of stem cells made them distinguished from traditional immunosuppressive drugs. As a new biotherapy, MSCs open a new way for treating auto-immune disease, besides hematopoietic stem cells. Oncogenicity should be further identified and effectively prevented, which may be a main study direction in the field of MSCs. MSC for autoimmune diseases should be strictly kept. There is not enough evidence for replacing the traditional immunosuppressants.

中图分类号: